Project PROTECT Milestone: Angels for Change and Fagron Sterile Services, US, have strengthened the U.S. Supply of Sterile Water for Injection (SWFI)
FOR IMMEDIATE RELEASE
Tampa, FL – March 17th, 2026, 9:00AM CST — Angels for Change (A4C) today announced that Fagron Sterile Services’ (FSS) 2025 Project Protect grant for Sterile Water for Injection (SWFI) production is now fully production-ready, marking a significant milestone in strengthening the nation’s supply of critical injectable medicines.
This achievement represents the second time Angels for Change has partnered with Fagron Sterile Services through its Project Protect grant program, which invests in domestic manufacturing to prevent drug shortages before patients are impacted.
The first grant, supporting Dextrose 70% (a vital sterile injectable medication) helped protect more than 1,000 patients during the IV fluid shortage in fall 2024. Through this continued collaboration, A4C and FSS are advancing proactive, sustainable solutions that address shortages before patients are harmed.
Importantly, Fagron has strategically used both grants for capital investments in domestic production capacity. These investments not only protect A4C designated medications but also expand FSS’s ability to support a broader range of vulnerable sterile injectable medicines across the U.S. healthcare system.
“By investing in infrastructure—not just individual products—we are building long-term resilience in the drug supply,” said Laura Bray, Founder and President of Angels for Change. “FSS has shown a strong commitment to patient care by using grant funding to strengthen domestic manufacturing in ways that benefit far more than a single medication or patient population.”
With the new sterile water production now online, FSS is positioned to increase reliability, responsiveness, and redundancy in sterile injectable manufacturing, key to patient care and mitigating harm during future shortages.
“Our partnership with Angels for Change allows us to make meaningful, lasting capital investments that expand our production capabilities,” said Ray Dixon, Senior Vice President of Fagron Sterile Services. “These improvements enable us to support not only A4C protected medicines like Dextrose 70%, and SWFI but also additional high-risk medications relied upon by hospitals and patients nationwide.”
Angels for Change’s Project Protect grant program focuses on upstream solutions partnering with US manufacturers to build onshore redundancy of shortage vulnerable essential medicines protecting US patients.
About Project PROTECT
Project PROTECT is a national program that provides grants to U.S.-based 503B outsourcing facilities to manufacture essential medications at risk of shortage proactively. By establishing ready-to-activate domestic capacity, the program strengthens national preparedness and protects patient access to vulnerable therapies. Angels for Change has built onshore readiness for 13 at-risk medicines; nine are now ready to supply US citizens, and three have already been used during national shortages, helping protect over 750,000 patient treatments.
Learn more: www.angelsforchange.org/project-protect
About Angels for Change
Angels for Change is a nonprofit patient-advocacy organization dedicated to ending drug shortages through advocacy, awareness, and strengthening the resilience of the pharmaceutical supply chain. As the operator of the nation’s only Drug Shortage Hotline, Angels for Change partners across healthcare, supply chain, manufacturing, and government to ensure patients receive lifesaving medicines when they need them.
Learn more: www.angelsforchange.org
About Fagron Sterile Services US
Fagron Sterile Services US (FSS) is a leading 503B outsourcing partner providing ready-to-administer sterile medications to healthcare providers nationwide. FSS plays a critical role in patient safety and drug supply resilience. Learn more: www.fagronsterile.com
